-
公开(公告)号：US20170348294A1
公开(公告)日：2017-12-07
申请号：US15686919
申请日：2017-08-25
Applicant: Novartis AG
Inventor： Markus FENDT , Dominik FEUERBACH , Sjoerd Jehannes FINNEMA , Baltazar GOMEZ-MANCILLA , Christer HALLDIN , Donald JOHNS , Cristina LOPEZ-LOPEZ , Kevin Hall MCALLISTER , Judit SOVAGO , Markus WEISS
IPC: A61K31/444 , A61K31/135 , A61K9/00 , A61K31/08 , A61K47/02 , A61K45/06
CPC classification number: A61K31/444 , A61K9/0019 , A61K31/08 , A61K31/135 , A61K45/06 , A61K47/02 , A61K2300/00
Abstract: The invention concerns the use of certain alpha 7 nicotinic acetylcholine receptor agonist for the facilitation of emergence from general anesthesia.
-
公开(公告)号：US20240082215A1
公开(公告)日：2024-03-14
申请号：US18266917
申请日：2021-12-09
Applicant: Novartis AG , Yale University
Inventor： Fabrizio GASPARINI , Baltazar GOMEZ-MANCILLA , John KRYSTAL , Vincent MALATERRE , Stephanie O'MALLEY , Godfrey PEARLSON , Marc POTENZA
IPC: A61K31/404 , A61P25/30
CPC classification number: A61K31/404 , A61P25/30
Abstract: The present invention relates to the use of mavoglurant in the treatment of gambling disorder. The present invention also relates to the use of mavoglurant in the treatment of gaming disorder.
-
3.发明公开公开(公告)号：US20240216369A1
公开(公告)日：2024-07-04
申请号：US17755435
申请日：2020-10-30
Applicant: Novartis AG
Inventor： Martin BEIBEL , Beth BOROWSKY , Jang-Ho CHA , Thomas FALLER , Baltazar GOMEZ-MANCILLA , Caroline GUBSER KELLER , Marc LAISNEY , Wen LIN , Nicole RENAUD , Rajeev SIVASANKRAN
CPC classification number: A61K31/501 , A61K9/0053 , A61K9/08 , A61K45/06 , A61K47/40 , A61P25/28
Abstract: Use of a splicing modulator for a treatment slowing progression of Huntington's disease.
-
Patent Agency Ranking
公开(公告)号：US20240041853A1
公开(公告)日：2024-02-08
申请号：US18255423
申请日：2021-12-03
Applicant: Novartis AG
Inventor： Jang-Ho CHA , Thomas FALLER , Baltazar GOMEZ-MANCILLA , Dimitris PAPANICOLAOU , Carman-Gabriela SERBAN , Florian VON RAISON
IPC: A61K31/4439 , A61K45/06 , A61P25/24
CPC classification number: A61K31/4439 , A61K45/06 , A61P25/24
Abstract: The invention relates to a dosage regimen of Compound (I), or a pharmaceutically acceptable salt thereof, for the treatment of diseases or disorders mediated by negative allosteric modulation or inhibition of NR2B-NMDA receptor including, but not limited to, major depressive disorder, treatment resistant depression and suicidality. The invention also relates to the use of Compound (I), or a pharmaceutically acceptable salt thereof, in the treatment of major depressive disorder in patients with suicidal ideation with intent.
-
5.发明公开公开(公告)号：US20230270720A1
公开(公告)日：2023-08-31
申请号：US18005364
申请日：2021-07-15
Applicant: Novartis AG
IPC: A61K31/404 , A61P25/36
CPC classification number: A61K31/404 , A61P25/36
Abstract: The invention relates to the use of mavoglurant, or a pharmaceutically acceptable salt thereof: in the reduction of opioid use by an opioid use disorder patient; in preventing relapse into opioid use by an opioid use disorder patient; in the promotion of opioid abstinence by an opioid use disorder patient; in the treatment of the symptoms of depression or anxiety associated with opioid use disorder.
-
公开(公告)号：US20220175793A1
公开(公告)日：2022-06-09
申请号：US17310287
申请日：2020-01-28
Applicant: NOVARTIS AG
IPC: A61K31/551 , A61K45/06 , A61P25/04
Abstract: The invention relates to the use of a mGluR5 antagonist for the treatment of opioid analgesic tolerance associated with chronic opioid use in chronic pain.
-
公开(公告)号：US20220211679A1
公开(公告)日：2022-07-07
申请号：US17700469
申请日：2022-03-21
Applicant: Novartis AG
Inventor： Markus FENDT , Dominik FEUERBACH , Donald JOHNS , Cristina LOPEZ-LOPEZ , Kevin Hall MCALLISTER , Judit SOVAGO , Markus WEISS , Baltazar GOMEZ-MANCILLA
IPC: A61K31/444 , A61K9/00 , A61K45/06 , A61K47/02 , A61K31/08 , A61K31/135
Abstract: The invention concerns the use of certain alpha 7 nicotinic acetylcholine receptor agonists for the treatment, amelioration, prevention or delay of progression of fatigue, narcolepsy, excessive daytime sleepiness, nocturnal sleep disturbance, and/or cataplexy.
-
公开(公告)号：US20150313884A1
公开(公告)日：2015-11-05
申请号：US14799744
申请日：2015-07-15
Applicant: Novartis AG
Inventor： Markus FENDT , Dominik FEUERBACH , Sjoerd Johannes FINNEMA , Baltazar GOMEZ-MANCILLA , Christer HALLDIN , Donald JOHNS , Cristina LOPEZ-LOPEZ , Kevin Hall MCALLISTER , Judit SOVAGO , Markus WEISS
IPC: A61K31/444
CPC classification number: A61K31/444 , A61K9/0019 , A61K31/08 , A61K31/135 , A61K45/06 , A61K47/02 , A61K2300/00
Abstract: The invention concerns the use of certain alpha 7 nicotinic acetylcholine receptor agonist for the facilitation of emergence from general anesthesia.
Abstract translation: 本发明涉及某些α7烟碱乙酰胆碱受体激动剂用于促进全身麻醉的出现。
-
-
-
-
-
-
-
Search Results
8
records
(took 0.015 seconds)
